FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2597457698> ?p ?o ?g. }

• W2597457698 abstract "Abstract To develop a prognostic scoring system tailored for therapy-related myelodysplastic syndromes (tMDS), we put together a database containing 1933 patients (pts) with tMDS from Spanish, German, Swiss, Austrian, US, Italian, and Dutch centers diagnosed between 1975-2015. Complete data to calculate the IPSS and IPSS-R were available in 1603 pts. Examining different scoring systems, we found that IPSS and IPSS-R do not risk stratify tMDS as well as they do primary MDS (pMDS), thereby supporting the need for a tMDS-specific score (Kuendgen et al., ASH 2015). The current analysis focuses on cytogenetic information as a potential component of a refined tMDS score, based on this large, unique patient cohort. Of the 1933 pts, 477 had normal karyotype (KT), 197 had missing cytogenetics, while 467 had a karyotype not readily interpretable. Incomplete karyotype descriptions will be reedited for the final evaluation. Of the remaining 1269 pts the most frequent cytogenetic abnormalities (abn) were: -7, del(5q), +mar, +8, del(7q), -5, del(20q), -17, -18, -Y, del(12p), -20, and +1 with >30 cases each. Frequencies are shown in Table 1. Some abn were observed mostly or solely within complex KTs, such as monosomies, except -7. Others, like del(20q) or -Y, are mainly seen as single or double abn, while del(5q), -7, or del(7q) are seen in complex as well as non-complex KTs. The cytogenetic profile overlapped with that of pMDS (most frequent abn: del(5q), -7/del(7q), +8, -18/del(18q), del(20q), -5, -Y, -17/del(17p), +21, and inv(3)/t(3q) (Schanz et al, JCO 2011)), with notable differences including overrepresentation of complete monosomies, a higher frequency of -7 or t(11q23), and a more frequent occurrence of cytogenetic subtypes in complex KTs, which was especially evident in del(5q) occurring as a single abn in 16%, compared to 70% within a complex KT. IPSS-R cytogenetic groups were distributed as follows: Very Good (2%), Good (35%), Int (17%), Poor (15%), Very Poor (32%). Regarding the number of abn (including incomplete KT descriptions) roughly 30% had a normal KT, 20% 1, 10% 2, and 40% ≥3 abn, compared to pMDS: 55% normal KT, 29% 1, 10% 2, and 6% ≥3 abn. To be evaluable for prognostic information, abn should occur in a minimum of 10 pts. As a single aberration this was the case for -7, +8, del(5q), del(20q), del(7q), -Y, and t(11;varia) (q23;varia). Of particular interest, there was no apparent prognostic difference between -7 and del(7q); del(5q) as a single abn was associated with a relatively good survival, while the prognosis was poor with the first additional abn; t(11q23) occurred primarily as a single abn and was associated with an extremely poor prognosis, and prognosis of pts with ≥4 abn was dismal independent of composition (Table 1). To develop a more biologically meaningful scoring system containing homogeneous and prognostically stable groups, we will further combine subgroups with different abn leading to the same cytogenetic consequences. For example, deletions, unbalanced translocations, derivative chromosomes, dicentric chromosomes of 17p, and possibly -17 all lead to a loss of genetic material at the short arm of this respective chromosome affecting TP53. Further information might be derived from analyses of the minimal common deleted regions. For some abn, like del(11q), del(3p), and del(9q), this can be refined to one chromosome band only (table 1). Conclusion: Development of a robust scoring system for all subtypes of tMDS is challenging using existing variables. This focused analysis on the cytogenetic score component shows that favorable KTs are evident in a substantial proportion of pts, in contrast to historic data describing unfavorable cytogenetics in the majority of pts. Although complex and monosomal KTs are overrepresented, this suggests the existence of distinct tMDS-subtypes, although some of these cases might not be truly therapy-induced despite a history of cytotoxic treatment. The next steps will be to analyze the prognosis of the different groups, develop a tMDS cytogenetic score, and examine minimal deleted regions to identify candidate genes for development of tMDS, as well as to describe the possible influence of different primary diseases and treatments (radio- vs chemotherapy, different drugs) on induction of cytogenetic subtypes. Our detailed analysis of tMDS cytogenetics should reveal important prognostic information and is likely to help understand mechanisms of MDS development. Disclosures Komrokji: Novartis: Consultancy, Speakers Bureau; Celgene: Membership on an entity's Board of Directors or advisory committees, Research Funding. Sole:Celgene: Membership on an entity's Board of Directors or advisory committees. Sekeres:Celgene: Membership on an entity's Board of Directors or advisory committees; Millenium/Takeda: Membership on an entity's Board of Directors or advisory committees. Roboz:Cellectis: Research Funding; Agios, Amgen, Amphivena, Astex, AstraZeneca, Boehringer Ingelheim, Celator, Celgene, Genoptix, Janssen, Juno, MEI Pharma, MedImmune, Novartis, Onconova, Pfizer, Roche/Genentech, Sunesis, Teva: Consultancy. Steensma:Amgen: Consultancy; Genoptix: Consultancy; Janssen: Consultancy; Celgene: Consultancy; Millenium/Takeda: Consultancy; Ariad: Equity Ownership. Schlenk:Pfizer: Honoraria, Research Funding; Amgen: Research Funding. Valent:Amgen: Honoraria; Deciphera Pharmaceuticals: Research Funding; Celgene: Honoraria, Research Funding; Novartis: Honoraria, Research Funding; Ariad: Honoraria, Research Funding; Deciphera Pharmaceuticals: Research Funding. Giagounidis:Celgene Corporation: Consultancy. Giagounidis:Celgene Corporation: Consultancy. Platzbecker:Celgene Corporation: Honoraria, Research Funding; TEVA Pharmaceutical Industries: Honoraria, Research Funding; Novartis: Honoraria, Research Funding; Janssen-Cilag: Honoraria, Research Funding; Amgen: Honoraria, Research Funding. Lübbert:Janssen-Cilag: Other: Travel Funding, Research Funding; Celgene: Other: Travel Funding; Ratiopharm: Other: Study drug valproic acid." @default.
• W2597457698 created "2017-04-07" @default.
• W2597457698 creator A5000776864 @default.
• W2597457698 creator A5005172825 @default.
• W2597457698 creator A5006306448 @default.
• W2597457698 creator A5010075752 @default.
• W2597457698 creator A5011302710 @default.
• W2597457698 creator A5012863731 @default.
• W2597457698 creator A5013460374 @default.
• W2597457698 creator A5017225753 @default.
• W2597457698 creator A5017309464 @default.
• W2597457698 creator A5021490305 @default.
• W2597457698 creator A5023726309 @default.
• W2597457698 creator A5024908600 @default.
• W2597457698 creator A5025663121 @default.
• W2597457698 creator A5025857936 @default.
• W2597457698 creator A5027784978 @default.
• W2597457698 creator A5035426042 @default.
• W2597457698 creator A5035609080 @default.
• W2597457698 creator A5041683169 @default.
• W2597457698 creator A5042260179 @default.
• W2597457698 creator A5043852143 @default.
• W2597457698 creator A5044033798 @default.
• W2597457698 creator A5045998799 @default.
• W2597457698 creator A5047951694 @default.
• W2597457698 creator A5049511411 @default.
• W2597457698 creator A5050011235 @default.
• W2597457698 creator A5052934298 @default.
• W2597457698 creator A5053949970 @default.
• W2597457698 creator A5054404140 @default.
• W2597457698 creator A5055740968 @default.
• W2597457698 creator A5056081193 @default.
• W2597457698 creator A5056987348 @default.
• W2597457698 creator A5061026876 @default.
• W2597457698 creator A5061663931 @default.
• W2597457698 creator A5063154849 @default.
• W2597457698 creator A5063825892 @default.
• W2597457698 creator A5066001318 @default.
• W2597457698 creator A5068674008 @default.
• W2597457698 creator A5068724005 @default.
• W2597457698 creator A5071555665 @default.
• W2597457698 creator A5078746528 @default.
• W2597457698 creator A5079124367 @default.
• W2597457698 creator A5080057087 @default.
• W2597457698 creator A5080192861 @default.
• W2597457698 creator A5080563231 @default.
• W2597457698 creator A5082287365 @default.
• W2597457698 creator A5090527595 @default.
• W2597457698 creator A5090912200 @default.
• W2597457698 date "2016-12-02" @default.
• W2597457698 modified "2023-10-18" @default.
• W2597457698 title "Frequency and Prognostic Significance of Cytogenetic Abnormalities in 1269 Patients with Therapy-Related Myelodysplastic Syndrome - a Study of the International Working Group (IWG-PM) for Myelodysplastic Syndromes (MDS)" @default.
• W2597457698 doi "https://doi.org/10.1182/blood.v128.22.112.112" @default.
• W2597457698 hasPublicationYear "2016" @default.
• W2597457698 type Work @default.
• W2597457698 sameAs 2597457698 @default.
• W2597457698 citedByCount "2" @default.
• W2597457698 countsByYear W25974576982020 @default.
• W2597457698 crossrefType "journal-article" @default.
• W2597457698 hasAuthorship W2597457698A5000776864 @default.
• W2597457698 hasAuthorship W2597457698A5005172825 @default.
• W2597457698 hasAuthorship W2597457698A5006306448 @default.
• W2597457698 hasAuthorship W2597457698A5010075752 @default.
• W2597457698 hasAuthorship W2597457698A5011302710 @default.
• W2597457698 hasAuthorship W2597457698A5012863731 @default.
• W2597457698 hasAuthorship W2597457698A5013460374 @default.
• W2597457698 hasAuthorship W2597457698A5017225753 @default.
• W2597457698 hasAuthorship W2597457698A5017309464 @default.
• W2597457698 hasAuthorship W2597457698A5021490305 @default.
• W2597457698 hasAuthorship W2597457698A5023726309 @default.
• W2597457698 hasAuthorship W2597457698A5024908600 @default.
• W2597457698 hasAuthorship W2597457698A5025663121 @default.
• W2597457698 hasAuthorship W2597457698A5025857936 @default.
• W2597457698 hasAuthorship W2597457698A5027784978 @default.
• W2597457698 hasAuthorship W2597457698A5035426042 @default.
• W2597457698 hasAuthorship W2597457698A5035609080 @default.
• W2597457698 hasAuthorship W2597457698A5041683169 @default.
• W2597457698 hasAuthorship W2597457698A5042260179 @default.
• W2597457698 hasAuthorship W2597457698A5043852143 @default.
• W2597457698 hasAuthorship W2597457698A5044033798 @default.
• W2597457698 hasAuthorship W2597457698A5045998799 @default.
• W2597457698 hasAuthorship W2597457698A5047951694 @default.
• W2597457698 hasAuthorship W2597457698A5049511411 @default.
• W2597457698 hasAuthorship W2597457698A5050011235 @default.
• W2597457698 hasAuthorship W2597457698A5052934298 @default.
• W2597457698 hasAuthorship W2597457698A5053949970 @default.
• W2597457698 hasAuthorship W2597457698A5054404140 @default.
• W2597457698 hasAuthorship W2597457698A5055740968 @default.
• W2597457698 hasAuthorship W2597457698A5056081193 @default.
• W2597457698 hasAuthorship W2597457698A5056987348 @default.
• W2597457698 hasAuthorship W2597457698A5061026876 @default.
• W2597457698 hasAuthorship W2597457698A5061663931 @default.
• W2597457698 hasAuthorship W2597457698A5063154849 @default.
• W2597457698 hasAuthorship W2597457698A5063825892 @default.
• W2597457698 hasAuthorship W2597457698A5066001318 @default.
• W2597457698 hasAuthorship W2597457698A5068674008 @default.
• W2597457698 hasAuthorship W2597457698A5068724005 @default.
• W2597457698 hasAuthorship W2597457698A5071555665 @default.
• W2597457698 hasAuthorship W2597457698A5078746528 @default.
• W2597457698 hasAuthorship W2597457698A5079124367 @default.

• next